 The objective for Part 2 is to evaluate the objective response rate stratified by Kirsten Rat Sarcoma Virus Oncogene KRAS status wild-type versus mutant in patients with Metastatic Colorectal Cancer treated with the combination of panitumumab and conatumumab tolerable dose identified in part 1. 